Biofilm compared to conventional antimicrobial susceptibility of stenotrophomonas maltophilia isolates from cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1546-1548

  Wu, Kitty ^a   Yau, Yvonne C W ^a   Matukas, Larissa ^b   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTAZIDIME; CLAVULANIC ACID; COLISTIN; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; SULFAMETHOXAZOLE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CYSTIC FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; PLANKTON; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BIOFILMS; CHILD; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PLANKTON; STENOTROPHOMONAS MALTOPHILIA;

EID: 84874072084     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02215-12     Document Type: Article

References (28)

1. Gibson RL, Burns JL, Ramsey BW. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918 -951.
2. Ballestero S, Virseda I, Escobar H, Suarez L, Baquero F. 1995. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 14:728 -729.
3. Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Barmeier H, Ratjen F. 2005. Prospective evaluation of emerging bacteria in cystic fibrosis. J. Cyst. Fibros. 4:41- 48.
4. Pompilio A, Crocetta V, Confalone P, Nicoletti M, Petrucca A, Guarnieri S, Fiscarelli E, Savini V, Piccolomini R, Di Bonaventura G. 2010. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol. 10:102.
5. Keays T, Ferris W, Vandemheen KL, Chan F, Yeung SW, Mah TF, Ramotar K, Saginur R, Aaron SD. 2009. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J. Cyst. Fibros. 8:122-127.
6. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771- 1776.
8. Dales L, Ferris W, Vandemheen K, Aaron SD. 2009. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 28:1275-1279.
9. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168 -171.
10. Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. 2009. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:3923-3928.
11. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN. 2011. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 55:2636 -2640.
12. Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Yoon SS, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ, Hwang SH, McDermott TR, Ochsner UA. 2002. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv. Drug Deliv. Rev. 54:1425-1443.
13. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109:317-325.
14. Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, Macgowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G. 2011. EUCAST expert rules in antimicrobial susceptibility testing. Clin. Microbiol. Infect. [Epub ahead of print.] doi:10.1111/j.1469-0691.2011. 03703.x.
15. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. 2007. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg. Infect. Dis. 13:559 -565.
16. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ. 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36:1147-1155.
17. Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K. 2009. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother. 63:534 -542.
18. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob. Agents Chemother. 54:3702-3707.
19. Beringer P. 2001. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 7:434-440.
20. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C. 2001. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch. Dis. Child. 84:432- 433.
21. Leong KW, Ong S, Chee HL, Lee W, Kwa AL. 2010. Hypersensitivity pneumonitis due to high-dose colistin aerosol therapy. Int. J. Infect. Dis. 14:e1018-e1019.
22. Reed MD, Stern RC, O'Riordan MA, Blumer JL. 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41: 645-654.
23. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. [Epub ahead of print.] doi:10.1007/s00134 -012-2628-7.
24. Passerini de Rossi B, Garcia C, Calenda M, Vay C, Franco M. 2009. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with deviceassociated infections. Int. J. Antimicrob. Agents. 34:260 -264.
25. Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R. 2004. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob. Agents Chemother. 48:151-160.
26. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ. 2011. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 183:1510- 1516.
27. Waters V, Ratjen F. 2006. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev. Anti-Infect. Ther. 4:807- 819.
28. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. 2000. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 45:363-365.